Tenofovir reduces HK-2 cell viability
Cell-based study · HK-2 cells [1]
HK-2 cells were treated with Tenofovir, and viability was assessed using Trypan Blue Exclusion. Tenofovir diminished cell viability beginning at 24 h and continuing for 72 h compared with vehicle control.
| Endpoint | Reported result | Reference |
|---|---|---|
| cell viability in HK-2 cells using Trypan Blue Exclusion | Reported result 1.5, 3.0, 4.75, 14.5, or 28.8 μM TFV: TFV diminished cell viability beginning at 24 h and continuing for 72 h when compared to vehicle control. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 1.5, 3.0, 4.75, 14.5, or 28.8 μM
- Exposure duration
- 24, 48, or 72 h
- Method
- cells were treated
- Vehicle
- phosphate buffered saline (PBS)
- Co-treatment
- Other interventions in this design: bovine pituitary extract 50 μg/mL; recombinant epithelial growth factor 5 ng/mL. Compound effect isolated by the comparison: when compared to vehicle control.
Methods and source locations
Compound reported in the paper: Tenofovir
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.1. TFV Effects on Cell Viability (S5); 4. Materials and Methods > 4.2. Cell Lines and Tenofovir (TFV) Treatment (S38, S41, S42); 4. Materials and Methods > 4.3. Cell Viability (S49); Figure 2 legend (S93)
cell viability in HK-2 cells using Trypan Blue Exclusion: cell viability in HK-2 cells using Trypan Blue Exclusion; comparator: vehicle control — 2. Results > 2.1. TFV Effects on Cell Viability (S5); 4. Materials and Methods > 4.2. Cell Lines and Tenofovir (TFV) Treatment (S41); Figure 2 legend (S93)